Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The company also announced the publication of two peer-reviewed research papers in "Nature" Tuesday. The first paper highlights the discovery and preclinical characterization of RMC-7977, and the second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.
British arms maker BAE Systems PLC (OTC: BAESF) considered restarting production of the M777 howitzer, as the big gun’s performance on Ukrainian battlefields revived interest in the weapon.